Cargando…

Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease

With the introduction of more and more monoclonal antibodies selectively targeting various mediators of the immune system, together with Janus-Kinase (JAK)-inhibitors with variable affinities towards different JAK subtypes, the available therapeutic options for the treatment of inflammatory bowel di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fries, Walter, Basile, Giorgio, Bellone, Federica, Costantino, Giuseppe, Viola, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340637/ https://www.ncbi.nlm.nih.gov/pubmed/37443755 http://dx.doi.org/10.3390/cells12131722

Ejemplares similares

Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
por: Bellone, Federica, et al.
Publicado: (2023)

Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic
por: Viola, Anna, et al.
Publicado: (2021)

Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Alexithymia and Inflammatory Bowel Disease: A Systematic Review
por: Martino, Gabriella, et al.
Publicado: (2020)

User's guide to JAK inhibitors in inflammatory bowel disease
por: Spiewak, Ted A., et al.
Publicado: (2022)

A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy
por: Belvedere, Alessandra, et al.
Publicado: (2021)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases
por: Herrera-deGuise, Claudia, et al.
Publicado: (2023)

JAK1 inhibition and inflammatory bowel disease
por: Harris, Clare, et al.
Publicado: (2021)

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
por: Hsu, Leeyen, et al.
Publicado: (2014)

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Manguso, Francesco, et al.
Publicado: (2016)

Vitamin D and Inflammatory Bowel Disease
por: Ardesia, Marco, et al.
Publicado: (2015)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease
por: Yadav, Vipul, et al.
Publicado: (2022)

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice
por: Honap, Sailish, et al.
Publicado: (2023)

Efficacy of JAK inhibitors in Crohn’s Disease
por: Rogler, Gerhard
Publicado: (2020)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease
por: Wu, Guozhi, et al.
Publicado: (2021)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

Beyond Methotrexate and Biologics in RA – Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium
por: Chatzidionysiou, Katerina
Publicado: (2020)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

Safety of biologics in inflammatory bowel disease patients with COVID-19
por: Weissman, Simcha, et al.
Publicado: (2021)

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
por: Agrawal, Manasi, et al.
Publicado: (2020)

Oral surveillance and JAK inhibitor safety: the theory of relativity
por: Winthrop, Kevin L., et al.
Publicado: (2022)

Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
por: Wei, Dongfan, et al.
Publicado: (2023)

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
por: Herrera-Gómez, Ruth Gabriela, et al.
Publicado: (2022)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?
por: Fries, Walter, et al.
Publicado: (2022)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2019)

The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
por: Yan, Diqin, et al.
Publicado: (2022)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
por: Sarabia, Samantha, et al.
Publicado: (2022)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ikt5ucn104rmiv5ht717j0rcnv